I was floored (figuratively speaking) to receive a snail-mail message signed by Richard Thomas, Vice President, Global Diabetes, Smiths Medical North America, that Smiths is discontinuing the Cozmo insulin pump. For several reasons: not the least of which is that I use a Cozmo pump myself. And the fact that it was sent by snail-mail, rather than... Read more
Another cute acronym, NICE-SUGAR, is the acronym for "Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation," a study that was just published in the New England Journal of Medicine. The authors looked at intensive versus conventional glucose control in critically ill patients in intensive care units... Read more
Sometimes when I receive questions by e-mail, I would like to share my answers with everyone, not just the initial writer. The following e-mail concerns a question I'm frequently asked: whether a medical finding that's new for the patient is related to a diabetes drug.
The e-mail asked: "I have been using [drug's name deleted] for 2 years. I... Read more
Sodium-glucose transporter-2 (SGLT2) is the name of a "transporter protein" in the kidneys that has become a hot topic in diabetes research. In people with normal blood glucose (BG) levels, glucose is not excreted into the urine, but thanks to SGLT2, remains in the body. Which is a good thing: glucose represents a major fuel to keep the body's... Read more
President Obama today, March 9, 2009, increased hope throughout the medical community for future treatments of diabetes and many other disorders, as he reversed the misguided policy of the previous President, to allow much more flexibility in stem cell research, stating "scientists believe these tiny cells may have the potential to help us... Read more